Effects of betulinic acid on AKT/mTOR pathway in renal cell carcinoma

2022 ◽  
Vol 48 (1) ◽  
pp. 58-63
Author(s):  
Merve Nur Ataş ◽  
◽  
Barış Ertuğrul ◽  
Elif Sinem İplik ◽  
Bedia Çakmakoğlu ◽  
...  
2020 ◽  
Vol 489 ◽  
pp. 135-143 ◽  
Author(s):  
Antonios N. Gargalionis ◽  
Eleni Sarlani ◽  
Anastasios Stofas ◽  
Lina S. Malakou ◽  
Christos Adamopoulos ◽  
...  

2012 ◽  
Vol 30 (4) ◽  
pp. 356-361 ◽  
Author(s):  
Alvaro Pinto Marín ◽  
Andrés Redondo Sánchez ◽  
Enrique Espinosa Arranz ◽  
Pilar Zamora Auñón ◽  
Beatriz Castelo Fernández ◽  
...  

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 406-406
Author(s):  
Samuel D. Kaffenberger ◽  
Giovanni Ciriello ◽  
Andrew G. Winer ◽  
Martin Henner Voss ◽  
Jodi Kathleen Maranchie ◽  
...  

406 Background: Proteomics represents the ultimate convergence of DNA and expression alterations. We therefore sought to leverage TCGA reverse phase protein array (RPPA) data with an independent proteomic platform to identify druggable targets and pathways associated with prognosis in clear cell renal cell carcinoma (ccRCC). Methods: Unsupervised hierarchical consensus clustering was performed and differentially expressed proteins were identified for pathway analysis. Associations with clinicogenomic factors were assessed and Cox proportional hazards models were performed for disease-specific survival (DSS). Results: RPPA clustering of 324 patients from the ccRCC TCGA revealed 5 robust clusters characterized by alterations in specific pathways and divergent prognoses. Cluster 1 was characterized by poor DSS, decreased expression of receptor tyrosine kinases (RTK) and upregulation of the mTOR pathway. It was also associated with mTOR pathway genomic alterations, sarcomatoid histology and the ccb prognostic mRNA signature (all p<0.001). Cluster 2 was characterized by increased expression of RTKs and interestingly, had upregulation of the mTOR pathway with excellent DSS. After accounting for stage and grade, cluster designation remained independently associated with DSS (HR 0.23 for cluster 2, 95% CI 0.08-0.68; p=0.008). External validation was performed on a separate cohort of 189 patients with a different quantitative proteomics platform. A panel of phosphoproteins (pHER1, pHER2, pHER3, pSHC, pMEK, pAKT), highly discriminant between the most divergent RPPA clusters (1 and 2) was evaluated. Those at the highest quartile of activation in > 3 proteins were associated with improved DSS (HR 0.19, 95% CI 0.05-0.082; p=0.03). Patients with mTOR pathway activation segregated to those with coincident RTK activation (n=83) and those without (n=13). Conclusions: We have identified and validated proteomic signatures which cluster ccRCC patients into 5 prognostic groups. Furthermore, two distinct mTOR-activated clusters—one with high RTK activity and one with increased mTOR pathway genomic alterations were revealed, which may have prognostic and therapeutic implications.


2013 ◽  
Vol 105 (6) ◽  
pp. 424-432 ◽  
Author(s):  
Xiang Shu ◽  
Jie Lin ◽  
Christopher G. Wood ◽  
Nizar M. Tannir ◽  
Xifeng Wu

2020 ◽  
Vol 33 (12) ◽  
pp. 2580-2590
Author(s):  
Juan María Roldan-Romero ◽  
María Santos ◽  
Javier Lanillos ◽  
Eduardo Caleiras ◽  
Georgia Anguera ◽  
...  

2010 ◽  
Vol 183 (4S) ◽  
Author(s):  
Luciana Schultz ◽  
Roula Albadine ◽  
Jessica Hicks ◽  
Angelo De Marzo ◽  
Victor Reuter ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document